Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) will present a podium talk on its INTASYL siRNA Drug Technology at Advanced Therapies USA 2025 in Philadelphia on November 18, 2025. The presentation, titled "INTASYL® Synthesized siRNA Drug Technology Down-regulating Gene Expression," will be delivered by Melissa Maxwell, M.S. in the Innovation Showcase (Track 2, Seminar Theatre) at 1:15 PM EDT. The company described INTASYL and PH-762 as a promising approach to enhance cancer treatment and a potential non-surgical option for cutaneous carcinomas.

Event dates are November 18–19, 2025 at the Pennsylvania Convention Center.

Presenting INTASYL siRNA Drug Technology

King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation highlighting INTASYL^® siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania Convention Center from November 18-19, 2025.

Podium Presentation Details are as follows:

Title:	INTASYL® Synthesized siRNA Drug Technology Down-regulating Gene Expression
Presenting Author:	Melissa Maxwell, M.S.
Date:	November 18, 2025
Location:	Innovation Showcase (Track 2, Seminar Theatre)
Time:	1:15 PM EDT

 

"The INTASYL siRNA technology represents a promising approach to enhance cancer treatment." said Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals. "Further the INTASYL compound PH-762 may fulfill a medical need for a non-surgical treatment option for patients with cutaneous carcinomas."

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL^® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, expectations regarding timing of enrollment, the expectations that we have sufficient capital to complete the treatment phase of our ongoing Phase 1b clinical trial, and statements regarding our clinical strategy, development plans and timelines and other future events.  

 These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, results from our preclinical and clinical activities, our ability to execute on business strategies, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.  

Contact:

Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274676

FAQ

When will Phio Pharmaceuticals (NASDAQ: PHIO) present INTASYL at Advanced Therapies USA 2025?

Phio will present on November 18, 2025 at 1:15 PM EDT in the Innovation Showcase (Track 2, Seminar Theatre).

What is the title of Phio's podium presentation at Advanced Therapies USA 2025?

The presentation is titled "INTASYL® Synthesized siRNA Drug Technology Down-regulating Gene Expression."

Who is presenting Phio's INTASYL research at the conference (PHIO)?

The presenting author is Melissa Maxwell, M.S..

Where and when is Advanced Therapies USA 2025 taking place for PHIO's presentation?

The event is at the Pennsylvania Convention Center, Philadelphia, PA, on November 18–19, 2025.

What clinical program did Phio mention in the Advanced Therapies USA 2025 announcement?

The company referenced the INTASYL technology and the compound PH-762 as a potential non-surgical option for cutaneous carcinomas.

How can investors or attendees access Phio's conference presentation details for PHIO?

Presentation details list the title, presenter, date, location, and time: November 18, 2025 · 1:15 PM EDT · Innovation Showcase (Track 2).